Charis Eng1, 2, James G Herman3
& Stephen B Baylin3
1
Clinical Cancer Genetics Program, Ohio State University
Comprehensive Cancer Center, Columbus, Ohio
43210, USA.eng-1@medctr.osu.edu
2
Cancer Research Campaign Human Cancer Genetics Research
Group, University of Cambridge, Cambridge CB2 2QQ,
UK.jherman@welchlink.welch.jhu.edu
3
The Johns Hopkins Comprehensive Cancer Center and Department
of Medicine, Johns Hopkins Medical Institutions, Baltimore,
Maryland 21231, USA.sbaylin@welchlink.welch.jhu.edu
Restriction landmark genomic scanning applied to a broad variety of cancer
types can disclose tumour-specific and tumour-type−specific global methylation
profiles. This and other genome-scanning approaches allows the rapid analysis
of methylation profiles of thousands of genes in parallel—and promises
to identify new genes critical to carcinogenesis and other biological processes.
